摘要:
This invention relates to multipotential expanded mesenchymal precursor cell progeny (MEMPs). The present invention also relates to methods for producing MEMPs and to uses of MEMPs for therapeutic applications.
摘要:
The present invention provides: a method for producing mixed cells comprising cardiomyocytes, endothelial cells and mural cells from induced pluripotent stem cells, the method comprising (a) a step of producing cardiomyocytes from induced pluripotent stem cells and (b) a step of culturing the cardiomyocytes in the presence of VEGF; and a therapeutic agent for heart diseases, comprising the mixed cells produced by the method.
摘要:
This invention provides a skin substitute comprising epithelial cells and modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells, and methods for using the same. This invention also provides a method for transplanting cells capable of inducing hair follicles, comprising subdermally or intradermally delivering to a patient modified mesenchymal cells, wherein the modified mesenchymal cells have decreased TSC1/TSC2 function, increased mTORCI function, and/or decreased mTORC2 function compared to wild type mesenchymal cells.
摘要:
An object of the present invention is to provide a cell structure which can be produced within a short period of time and has a predetermined or larger size, and a method for producing the above-described cell structure. According to the present invention, there is provided a cell structure including: a biocompatible macromolecular block; and two or more kinds of cells, in which a plurality of the biocompatible macromolecular blocks are arranged in gaps between a plurality of the cells, and in which the two or more kinds of cells contain at least one kind of first cell selected from the group consisting of vascular endothelial cells, cardiac muscle cells, pancreatic islet cells, liver cells, epithelial cells, endothelial cells, nerve cells, embryonic stem cells, induced pluripotent stem cells, corneal epithelial cells, and retinal pigment epithelial cells, and at least one kind of second cell selected from the group consisting of mesenchymal cells, stromal cells, fibroblasts, smooth muscle cells, myoblasts, mesenchymal stem cells, adipose-derived stem cells, and umbilical cord-derived stem cells.
摘要:
Devices for implanting cells in a host body are described. The device comprises a porous scaffold comprising at least one chamber having a proximal end and a distal end, pores sized to facilitate growth of vascular and connective tissues into the at least one chamber and a polypropylene mesh. A portion of the porous scaffold is coated with one or more materials that stimulates tissue incorporation and angiogenesis. A further device comprises a porous scaffold comprising at least one chamber having a proximal end and a distal end, pores sized to facilitate growth of vascular and connective tissues into the at least one chamber, at least one removable plug configured to be positioned within the at least one chamber and a polypropylene mesh. Comprised with the chamber are stem cells which are immature, partially differentiated, or fully differentiated.
摘要:
The present invention relates to a method for preparing a skin substitute, to a method for preparing a dermal substitute, to a skin substitute, to a dermal substitute and to a kit for implementing the method. The present invention also relates to a graft consisting of a skin substitute and to the use thereof as a means of treating a skin disorder and/or a loss of skin substance. The present invention can be used in particular in the pharmacological, medical and clinical fields.
摘要:
A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted. The cells are specifically introduced to the hepato-pancreatic common duct of the subject for treatment of pancreatic conditions or to the bile duct wall near to the liver for treatment of liver conditions and allowed to migrate to the pancreas or to the liver and expand and then rebuild part or the entirety of the diseased or dysfunctional organ.